Atlas Trials

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

Clinical trial NCT01924793 · COMPLETED

Trial details

NCT number
NCT01924793
Sponsor
Ansun Biopharma, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Parainfluenza
Start date
2013-08-01
Primary completion
2017-05-01
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.